Clinical efficacy of intravitreal implant Ozurdex in combination with laser treatment in patients with retinal vein occlusions

Cover Page

Abstract


A clinical efficacy analysis of combined post-thrombotic retinopathy treatment using dexamethason intravitreal implant “Ozurdex” and retinal photocoagulation is presented. The medication promotes macular edema resorption and allows increasing visual acuity for a long period of time. Photocoagulation prevents complications, promotes edema and hemorrhage resorption. Visual acuity dynamics may be influenced by such factors as disease duration, lesion area, occlusion localization. The use of dexamethason intravitreal implant in combination with photocoagulation gives new options in treatment of patients with retinal vein occlusions

Anastasiya Viktorovna Kulagina

Railway clinical hospital

Email: kulaginaanastasya@yandex.ru
ophthalmologist

Evgeniy Gennad'evich Badazhkov

Eye microsurgery center “Finist”

Email: finist2002@mail.ru

Olga Gennad’evna Gusarevich

State Medical University

Email: olga.gusarevich@gmail.com

  1. Бойко Э. В., Шишкин М. М., Березин Ю. Д., Диодный лазер в офтальмологической операционной. СПб.; 2000.
  2. Краснов М. М., Димитрова В. Г., Переверзина О. К., Елисеева Е. Г. Лазерное лечение тромбоза ретинальных вен. Вестник офтальмологии. 1976; 3: 27-32
  3. Тульцева С. Н., Астахов Ю. С. Роль воспаления в патогенезе посттромботического макулярного отека. Современные направления медикаментозного лечения. Офтальмологические ведомости. 2012: 5 (4): 35-44.
  4. Тульцева С. Н., Нечипоренко П. А., Титаренко А. И. Использование интравитреального имплантата Озурдекс в терапии постокклюзионного макулярного отека. Офтальмологические ведомости. 2014; 7 (3): 5-16.
  5. Antonetti D. A., Barber A. J., Khin S., Lieth E., Tarbell J. M., Gardner T. W. Penn State Retina Research Group. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 1998; 47: 1953-9.
  6. Antonetti D. A., Wolpert E. B., De Maio L., Harhaj N. S., Scaduto R. C. Jr. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J. Neurochem. 2002; 80: 667-77.
  7. Augustin A. J., Sahel J. A., Cerulli L , Texier-Richard B., Buchholz P. M., Kobelt G. Treating retinal vein occlusions in France, Germany, and Italy: an analysis of treatment patterns, resource consumption, and costs. Eur. J. Ophthalmol. 2012; 22 (5): 776-84.
  8. Branch Vein Occlusion Study Group Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch. Ophthalmol. 1986; 104: 34-41.
  9. Brown D. M., Campochiaro P. A., Singh R. P., Li Z., Gray S., Saroj N., Rundle A. C., Rubio R. G., Murahashi W. Y. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117: 1124 -33.
  10. Campochiaro P. A., Heier J. S., Feiner L., Gray S., Saroj N., Rundle A. C., Murahashi W. Y., Rubio R. G. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117:.1102-12.
  11. Coscas G., Loewenstein A., Augustin A., Bandello F., Battaglia Parodi M., Lanzetta P., Monés J., de Smet M., Soubrane G., Staurenghi G. Management of Retinal Vein Occlusion - Consensus Document. Ophthalmologica. 2011; 226: 4-28.
  12. L’ Esperanse F. A. Ophthalmic Lasers photocoagulation, photoradiation and surgery. St. Louis: Mosby; 1983.
  13. Frangieh G. T., Green W. R., Barraquer-Somers E., Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch. Ophthalmol. 1982; 100: 1132-40.
  14. Green W. R., Chan C. C., Hutchins G. M., Terry J. M. Central retinal vein occlusions: A prospective histopathologic study of 29 eyes in 28 cases. Retina. 1981; 1: 27-55.
  15. Green W. R. Retina. In: Spencer W. H. (Ed). Ophthalmic pathology An Atlas and Textbook. 3rd Ed. Philadephia. WB Saunders; 1985.
  16. Haller J. A., Bandello F., Belfort R. Jr., Blumenkranz M. S., Gillies M., Heier J., Loewenstein A., Yoon Y. H., Jacques M. L., Jiao J., Li X. Y., Whitcup S. M. OZURDEX GENEVA Study Group. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Ophthalmology. 2010; 117: 1134-46.
  17. Haller J. A., Bandello F., Belfort R. Jr., Blumenkranz M. S., Gillies M., Heier J., Loewenstein A., Yoon Y. H., Jiao J., Li X. Y., Whitcup S. M. Ozurdex GENEVA Study Group, Li J. Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion. Twelve-Month Study Results. Ophthalmology. 2011; 118: 2453-60.
  18. Klein M. L., Pinkelstein D. Makular grid photocoagulation for- macular edema in central retinal vein occlusions. Arch. Ophthalmol. 1989; 107 (9): 1297-302.
  19. Kuppermann B. D., Blumenkranz M. S., Haller J. A., Williams G. A., Weinberg D. V., Chou C., Whitcup S. M. Dexamethasone DDS Phase II Study Group. Randomized Controlled Study of an Intravitreous Dexamethasone Drug Delivery System in Patients With Persistent Macular Edema. Arch. Ophthalmol. 2007; 125: 309-17.
  20. Mitchell P., Smith W., Chang A. Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study. Arch. Ophthalmol. 1996; 114: 1243-7.
  21. Nauck M., Karakiulakis G., Perruchoud A. P., Papakonstantinou E., Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur. J. Pharmacol. 1998; 341: 309-15.
  22. Nehme A., Edelman J. Dexamethasone Inhibits High Glucose-, TNF-, and IL-1-Induced Secretion of Inflammatory and Angiogenic Mediators from Retinal Microvascular Pericytes Investigative Ophthalmology & Visual Science. 2008: 49 (5); 2030-38.
  23. Noma H., Funatsu H., Mimura T., Harino S., Sone T., Hori S. Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humor of patients with macular edema and central retinal vein occlusion. Acta. Ophthalmol. 2010: 88 (6); 646-51
  24. Rehak J., Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr. Eye. Res. 2008; 33: 111-31.
  25. Rogers S., McIntosh R. L., Cheung N., Lim L., Wang J. J., Mitchell P., Kowalski J. W., Nguyen H., Wong T. Y. International Eye Disease Consortium. The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010; 117: 313-9.
  26. Royal College of Ophthalmologists. Retinal vein occlusion (RVO) interim guidelines. December 2010.
  27. The Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. Amer. J. Ophthalmol. 1984; 98: 271-82.
  28. The Branch Vein Occlusion Study Group: Argon laser scatter photocoagulation for prevention of ntovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch. Ophthalmol. 1986; 104: 34-41.
  29. The Central Vein Occlusion Study Group: Evaluation of grid pattern photocoagulation for macular edema in central vein occlusions. The CVOS M reportOphthalmology. 1995; 102: 1425-33.
  30. Yau J. W., Lee P., Wong T. Y., Best J., Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J. 2008; 38: 904 -10.

Views

Abstract - 388

PDF (Russian) - 235

Cited-By


PlumX


Copyright (c) 2015 Kulagina A.V., Badazhkov E.G., Gusarevich O.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.